H1N1 Infection - Pipeline Insight, 2025

This “H1N1 infection - Pipeline Insight, 2025,” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in H1N1 infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

H1N1 infection Understanding

H1N1 infection: Overview

H1N1 influenza, commonly referred to as swine flu, is an infectious disease caused by the H1N1 strain of the influenza A virus. This virus is notable for its rapid transmission and ability to cause significant respiratory illness in humans. The H1N1 strain gained global prominence during the 2009 pandemic, which originated in Mexico and quickly spread worldwide. This particular strain is a reassortant virus, meaning it contains genetic material from human, swine, and avian influenza viruses, contributing to its unique properties and impact.

The transmission of H1N1 occurs primarily through respiratory droplets when an infected person coughs or sneezes. It can also spread by touching surfaces contaminated with the virus and then touching the nose or mouth. Symptoms of H1N1 infection are similar to those of seasonal flu and include fever, cough, sore throat, body aches, headache, chills, and fatigue. In some cases, individuals may also experience vomiting and diarrhea. While most cases are mild, H1N1 can lead to severe illness, particularly in young children, elderly individuals, pregnant women, and those with underlying health conditions.

Diagnosis of H1N1 typically involves clinical assessment and laboratory testing of respiratory specimens to confirm the presence of the virus. Treatment primarily focuses on relieving symptoms, with antiviral medications like oseltamivir (Tamiflu) and zanamivir (Relenza) recommended for severe cases or individuals at high risk of complications. These antivirals are most effective when administered within 48 hours of symptom onset. Additionally, supportive care such as hydration, rest, and over-the-counter medications for fever and pain relief play a critical role in managing the infection.

Prevention strategies for H1N1 include annual vaccination, which is the most effective way to protect against the virus. The H1N1 strain is now a component of the seasonal influenza vaccine, offering broad protection against multiple influenza viruses. Public health measures such as hand hygiene, respiratory etiquette (covering coughs and sneezes), and avoiding close contact with infected individuals are also crucial in controlling the spread of H1N1. During outbreaks, authorities may implement additional measures like social distancing, school closures, and travel restrictions to mitigate transmission.

'H1N1 infection - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the H1N1 infection pipeline landscape is provided which includes the disease overview and H1N1 infection treatment guidelines. The assessment part of the report embraces, in depth H1N1 infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, H1N1 infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence H1N1 infection R&D. The therapies under development are focused on novel approaches to treat/improve H1N1 infection.

H1N1 infection Emerging Drugs Chapters

This segment of the H1N1 infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

H1N1 infection Emerging Drugs

SAB 176: SAB Biotherapeutics

SAB-176 is a multivalent, broadly neutralizing fully-human polyclonal antibody therapeutic candidate in development for the treatment or prevention of severe influenza. The novel, specifically-targeted therapeutic leverages the natural human biological immune response to specifically bind to Type A and Type B influenza viruses. Like vaccines, it can be modified to address annual strain changes, when needed, to maintain broader coverage as the flu virus mutates. Preclinical data suggests that SAB-176 offers broad protection against diverse influenza strains. The drug is currently in Phase II stage of clinical trial evaluation to treat Influenza A H1N1.

CodaVax-H1N1: Codagenix

A live-attenuated influenza vaccine, CodaVax-H1N1, is being developed by Codagenix. The vaccine enables presentation of conserved antigens of the wild-type virus, demonstrating universal potential in primate models and thus the potential to provide multi-season protection when developed into its final quadrivalent formulation. Currently, it is in Phase I stage of clinical trial evaluation to treat H1N1 infection.

H1N1 infection: Therapeutic Assessment

This segment of the report provides insights about the different H1N1 infection drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in H1N1 infection

There are approx. 18+ key companies which are developing the therapies for H1N1 infection. The companies which have their H1N1 infection drug candidates in the most advanced stage, i.e. Phase II include, SAB Biotherapeutics.

Phases

The report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

H1N1 infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

H1N1 infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses H1N1 infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging H1N1 infection drugs.

H1N1 infection Report Insights

• H1N1 infection Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

H1N1 infection Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing H1N1 infection drugs?
• How many H1N1 infection drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of H1N1 infection?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the H1N1 infection therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for H1N1 infection and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• SAB Biotherapeutics
• Codagenix, Inc
• Cocrystal Pharma
• Collaborations Pharmaceuticals
• Vaxart, Inc.

Adimmune Corporation

• Model Medicines
• NanoViricides
• Ansun Biopharma
• Immune Therapeutics, Inc.

Ena Respiratory

• EpiVax, Inc.

Mayly Life Sciences

• Recce Pharmaceuticals
• Vivaldi Biosciences
• Sonnet BioTherapeutics

Key Products

• SAB 176
• CODA-VAX H1N1
• CC-42344
• MDL-001
• DAS-181
• INNA-051
• RECCE 327
• DeltaFLU
• SON-1010

This product will be delivered within 1-3 business days.